<DOC>
	<DOCNO>NCT00004208</DOCNO>
	<brief_summary>The main objective trial evaluate efficacy toxicity intensive immuno-suppression ATG + CSA versus best supportive care patient transfusion dependent low intermediate risk myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>Antithymocyte Globulin Cyclosporine Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>This trial answer question whether immuno-suppression improves hematopoesis reduces transfusion requirement analogous patient aplastic anemia short-term outcome , whether immuno-suppression accelerates leukemic transformation influence survival long-term outcome . Primary endpoint : best response ( CR + PR ) rate month 6</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Hypoplastic MDS , MDS subtype RA , RAS RAEB ≤ 10 % blast , RAEB 1020 % blast patient refuse eligible MDS high risk protocol ( EORTC 06961 ) Transfusion dependence &lt; 24 month neutrophils &lt; 0.5 × 109/l . ECOG/SAKK performance status ≤ 2 Age &gt; 18 year No active uncontrolled infection No prior chemotherapy radiotherapy No history heart failure , clinically relevant cardiac arrhythmia hematooncological disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>